The crystal structure is shown in the gure. Tables 1-3 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.
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Source of material
4-Fluorobenzyl chloride (1.45 g, 0.01 mol) and anhydrous potassium carbonate (1.38 g, 0.01 mol) were added to a solution of 6-(2-methylpropyl)-2-thiouracil-5-carbonitrile (2.09 g, 0.01 mol) in N,N-dimethylformamide (10 mL) and the mixture was stirred at room temperature for 12 hours. Water (15 mL) was gradually added and the mixture was stirred 
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Discussion
Various pyrimidine non-nucleoside analogues have been developed as potent chemotherapeutic agents with anticancer, antiviral, antifungal and antibacterial activities. Nonnucleoside pyrimidine-based analogues have emerged as useful therapies against human immunode ciency viruses (HIV) [1] [2] [3] [4] , hepatitis B viruses (HBV) [5] , herpes simplex viruses (HSV) [6, 7] , varicella-zoster virus (VZV) [8] and in uenza viruses [9] . A large number of pyrimidine-based antimetabolites are currently used as potent and selective anticancer activity [10] [11] [12] . In addition, marked antibacterial and antifungal activities were observed for several pyrimidine-5-carbonitrile derivatives [13] [14] [15] [16] [17] . Here, we report the crystal structure of the recently synthesized [16] title compound (C 16 H 16 FN 3 OS).
The crystal structure of the title compound contains one molecule in the asymmetric unit. With respect to the pyrimidinyl ring, (C1/N1/C2/C3/C4/N2), the uorobenzene ring (C11-C16) form dihedral angle of 51.2 (1)°. The molecular packing is stabilized by one intermolecular hydrogen bond where O1 acts as hydrogen bond acceptor and the NH group (N1) is the hydrogen bond donor. The H· · · O distance of the N1-H1· · · O1 hydrogen bond is 1.91(1) Å and the angle is 169.7(1)°.
